AVM Biotechnology Expands Executive Team in Preparation for Oncology & COVID-19 Clinical Trials, Appoints Janet R. Rea, MSPH, Chief Operating Officer
- Wednesday, July 8, 2020, 7:01
- Finance
- Add a comment
SEATTLE, July 8, 2020 /PRNewswire/ — Seattle’s AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin’s Lymphoma and is applying to begin trials treating moderate-severely ill…
About the Author
adminasapcorp has written 41555 stories on this site.